{"id":"49519205-f873-5ec3-a753-cd7c594a3fe6","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:cancer-serum-association","predicate":"reported_relationship","statement":"Higher serum ALCAR was associated with shorter progression-free survival in the reported ovarian-cancer cohort.","claim_class":"observational","status":"source_recorded","evidence_grade":"ungraded","direction":"neutral","is_public":true,"mechanism_event_id":"8cb206bd-c759-53c8-b936-c5dfa0af872c","mechanism_event_label":"Higher serum ALCAR was associated with shorter progression-free survival in the reported ovarian-cancer cohort.","subject":{"id":"37e9d890-b4e6-5225-83ce-e53183a9478f","slug":"human-plasma-alcar","display_name":"Human plasma acetylcarnitine concentration","entity_type_key":"cellular_process"},"object":{"id":"ecf8260e-08bb-5c00-8bff-868bba4c639b","slug":"human-ovarian-pfs-alcar","display_name":"Ovarian-cancer progression-free survival associated with serum ALCAR","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"8cb206bd-c759-53c8-b936-c5dfa0af872c","stable_key":"e3f6ce02-0bd7-5103-acc1-68503ab6751b:cancer-serum-association-event","event_type":"experimental_observation","label":"Higher serum ALCAR was associated with shorter progression-free survival in the reported ovarian-cancer cohort.","description":"### cancer-serum-association\n\nHigher serum ALCAR was associated with shorter progression-free survival in the reported ovarian-cancer cohort.\nObservational association, not an ALCAR supplementation trial. Tumor metabolism, disease burden and other factors may influence circulating ALCAR. No causal direction from the blood measurement is established.\nModel and exposure: Patient serum upper-versus-lower quartile analysis; Fig. 5h; log-rank HR 2.439, P=0.0364.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | 2026 | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"37e9d890-b4e6-5225-83ce-e53183a9478f","slug":"human-plasma-alcar","display_name":"Human plasma acetylcarnitine concentration","entity_type_key":"cellular_process"},"role":"recorded factor","stoichiometry":null,"state_label":"as reported","sequence_order":0,"notes":""},{"entity":{"id":"ecf8260e-08bb-5c00-8bff-868bba4c639b","slug":"human-ovarian-pfs-alcar","display_name":"Ovarian-cancer progression-free survival associated with serum ALCAR","entity_type_key":"cellular_process"},"role":"measured outcome","stoichiometry":null,"state_label":"not_reported","sequence_order":1,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_access","value_text":"Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Patient serum upper-versus-lower quartile analysis; Fig. 5h; log-rank HR 2.439, P=0.0364.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"interpretation_status","value_text":"Source-derived curation with stated access limits; ungraded, not independent replication.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"Acetyl-L-carnitine collection; exact intervention and molecular form govern interpretation.","comparator":null,"unit":null,"notes":"","entity":{"slug":"acetylcarnitine","display_name":"Acetyl-L-carnitine","entity_type_key":"small_molecule"}},{"dimension":"plain_language","value_text":"Higher serum ALCAR was associated with shorter progression-free survival in the reported ovarian-cancer cohort.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"source_locator","value_text":"Reviewed reference cancer-serum-association; Observational association, not an ALCAR supplementation trial. Tumor metabolism, disease burden and other factors may influence circulating ALCAR. No causal direction from the blood measurement is established.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"biomarker_context","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"325a8d5e-1c61-53b1-ad70-a91d69f2781a","evidence_kind":"source_excerpt","locator":"Lines 352-358","start_line":352,"end_line":358,"excerpt":"### cancer-serum-association\n\nHigher serum ALCAR was associated with shorter progression-free survival in the reported ovarian-cancer cohort.\nObservational association, not an ALCAR supplementation trial. Tumor metabolism, disease burden and other factors may influence circulating ALCAR. No causal direction from the blood measurement is established.\nModel and exposure: Patient serum upper-versus-lower quartile analysis; Fig. 5h; log-rank HR 2.439, P=0.0364.\nLimitations: Limited to the recorded preparation, model, exposure and endpoint. Does not establish a human dietary deficiency, clinical benefit or unique molecular mediation.\nReference: αKG-mediated carnitine synthesis drives DNA repair via histone acetylation. | 2026 | https://pubmed.ncbi.nlm.nih.gov/42203879/ | https://pmc.ncbi.nlm.nih.gov/articles/PMC13307467/ | https://doi.org/10.1038/s41586-026-10584-7 | Access: Primary full text: relevant Results/Methods and figure descriptions reviewed; supplements only where explicitly stated.","model_system":"Patient serum upper-versus-lower quartile analysis; Fig. 5h; log-rank HR 2.439, P=0.0364.","directness":"reported_statement","verification_status":"source_recorded","notes":"Original paraphrase in the retained reviewed reference, not a verbatim primary-paper quotation. Access level is explicit.","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"2588f904-245a-597a-8a12-65118013fb90","stable_key":"import-e3f6ce02-0bd7-5103-acc1-68503ab6751b","title":"Acetyl-L-carnitine: detailed mechanisms of action (reviewed 6 October 2026)","document_type":"imported_text","citation_label":"AI-assisted original review of primary studies and clearly identified official records. Exact primary access is stated; no independent replication is claimed.","file_path":"","sha256":"84cc82d6fbb0fd5d73c4ce779e9f88e7f0184ba2d29b18ad0f153815380f2975","revision_id":"dac7a950-dbe5-5c7a-9c70-2ea711d5c71a","review_status":"source_recorded","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}